Related Experiment Videos

[New developments in antithrombotic care]

J C Wautrecht1

  • 1Service de Pathologie Vasculaire, Hôpital Erasme, Bruxelles. jean.claude.wautrecht@erasme.ulb.ac.be

Revue Medicale De Bruxelles
|November 11, 2009
PubMed

Insights

New anticoagulants targeting Factor Xa and thrombin offer alternatives to traditional vitamin K antagonists (VKAs). These novel oral anticoagulants (NOACs) and others are poised to transform antithrombotic therapy, alongside improved VKA monitoring tools.

Area of Science:

  • Pharmacology and Thrombosis Research
  • Development of Novel Anticoagulant Therapies

Context:

  • Vitamin K antagonists (VKAs) have dominated oral anticoagulation for over 50 years.
  • Emerging direct oral anticoagulants (DOACs) and other agents are nearing clinical implementation.
  • Optimizing existing VKA therapy with anticoagulation clinics and point-of-care INR testing is also advancing.

Purpose:

  • To review the clinical potential of new anticoagulant drugs.
  • To discuss advancements in antithrombotic care.
  • To explore tools for enhancing traditional VKA anticoagulation management.

Summary:

  • New anticoagulants, including FXa inhibitors (e.g., apixaban, rivaroxaban) and thrombin inhibitors (e.g., dabigatran), are in late-stage trials.
  • Idraparinux, a long-acting fondaparinux derivative, inhibits FXa indirectly.
  • These agents represent a significant shift from VKA therapy in oral anticoagulation.

Impact:

  • These novel anticoagulants are expected to significantly impact daily clinical practice in antithrombotic management.
  • Improved monitoring of VKAs through specialized clinics and point-of-care testing offers enhanced patient self-management.
  • The introduction of these new drugs promises to modernize antithrombotic care.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...